Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) EBT (2016 - 2025)

Tg Therapeutics has reported EBT over the past 10 years, most recently at -$62.6 million for Q4 2025.

  • Quarterly results put EBT at -$62.6 million for Q4 2025, down 337.94% from a year ago — trailing twelve months through Dec 2025 was -$349000.0 (down 101.32% YoY), and the annual figure for FY2025 was -$349000.0, down 101.32%.
  • EBT for Q4 2025 was -$62.6 million at Tg Therapeutics, down from $25.9 million in the prior quarter.
  • Over the last five years, EBT for TGTX hit a ceiling of $113.9 million in Q3 2023 and a floor of -$94.0 million in Q4 2021.
  • Median EBT over the past 5 years was -$37.9 million (2022), compared with a mean of -$27.0 million.
  • Peak annual rise in EBT hit 507.05% in 2025, while the deepest fall reached 337.94% in 2025.
  • Tg Therapeutics' EBT stood at -$94.0 million in 2021, then rose by 14.49% to -$80.4 million in 2022, then soared by 82.55% to -$14.0 million in 2023, then skyrocketed by 287.72% to $26.3 million in 2024, then tumbled by 337.94% to -$62.6 million in 2025.
  • The last three reported values for EBT were -$62.6 million (Q4 2025), $25.9 million (Q3 2025), and $30.9 million (Q2 2025) per Business Quant data.